Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-1151
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Targeting the PI3K/Akt/mTOR Signalling Pathway in Cystic Fibrosis

Scientific Reports
Multidisciplinary
2017English

Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Absence of Appl2 Sensitizes Endotoxin Shock Through Activation of PI3K/Akt Pathway

Cell and Bioscience
BiochemistryGeneticsMolecular Biology
2014English

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

PI3K-PKB/Akt Pathway

Cold Spring Harbor perspectives in biology
BiochemistryGeneticsMolecular Biology
2012English

Applying 89Zr-Transferrin to Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy